Powder: -20°C for 3 years | In solvent: -80°C for 1 year
T0901317 是一种口服有效且高度选择性的LXR 激动剂,对 LXRα 的EC50为 20 nM。它激活FXR,EC50为 5 μM。它是RORα和RORγ双重反向激动剂,Ki 值分别为 132 nM 和 51 nM。它诱导细胞凋亡,并抑制低密度脂蛋白受体缺失小鼠动脉粥样硬化的发展。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 297 | 现货 | ||
10 mg | ¥ 477 | 现货 | ||
25 mg | ¥ 758 | 现货 | ||
50 mg | ¥ 997 | 现货 | ||
100 mg | ¥ 1,490 | 现货 | ||
200 mg | ¥ 2,390 | 现货 | ||
500 mg | ¥ 3,920 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 385 | 现货 |
产品描述 | T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively; it inhibits nuclear factor/κB (NF/κB). |
靶点活性 | FXR:5 μM(EC50), LXR:50 nM(EC50) |
体外活性 | T0901317 acts through LXR and in concert with its RXR heterodimerization partner induces the expression of the ABCA1 reverse cholesterol transporter. T0901317 upregulates expression of the ABCA1 gene associated with cholesterol efflux regulation and HDL metabolism.[1] T0901317 displays an EC50 of ~ 5 μM for activation of bile acid farnesoid X receptors (FXRs), 10-fold more potent than natural FXR ligand chenodeoxycholic acid. [2] T0901317, is also a high-affinity ligand for the xenobiotic receptor pregnane X receptor (PXR). T0901317 binds and activates PXR with the same nanomolar potency with which it stimulates LXR activity. T0901317 induces expression not only of LXR target genes, but also of PXR target genes in cells and animals, including the scavenger receptor CD36. [3] T0901317 decreases amyloid-β production in primary neurons in vitro. [4] T0901317 is found to directly bind to RORα and RORγ with high affinity (Ki = 132 and 51 nM, respectively), resulting in the modulation of the receptor's ability to interact with transcriptional cofactor proteins. T0901317 represses RORα/γ-dependent transactivation of ROR-responsive reporter genes and in HepG2 cells reduces recruitment of steroid receptor coactivator-2 by RORα at an endogenous ROR target gene (G6Pase). [5] |
体内活性 | T0901317 treatment of 11-week-old APP23 mice for 6 days shows a significant increase in ABCA1 expression and a decrease in the ratio of soluble APP (sAPP)β- to sAPPα-cleavage products. Most importantly, the treatment causes a statistically significant reduction in the levels of soluble Aβ40 and of Aβ42 in the brain these mice. [4] |
别名 | N-(2,2,2-三氟乙基)-N-[4-[2,2,2-三氟-1-羟基-1-(三氟甲基)乙基]苯基]苯磺酰胺 |
分子量 | 481.33 |
分子式 | C17H12F9NO3S |
CAS No. | 293754-55-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 48.1 mg/mL (100 mM)
Ethanol: 48.1 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.0776 mL | 10.3879 mL | 20.7758 mL | 51.9394 mL |
5 mM | 0.4155 mL | 2.0776 mL | 4.1552 mL | 10.3879 mL | |
10 mM | 0.2078 mL | 1.0388 mL | 2.0776 mL | 5.1939 mL | |
20 mM | 0.1039 mL | 0.5194 mL | 1.0388 mL | 2.597 mL | |
50 mM | 0.0416 mL | 0.2078 mL | 0.4155 mL | 1.0388 mL | |
100 mM | 0.0208 mL | 0.1039 mL | 0.2078 mL | 0.5194 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
T0901317 293754-55-9 Apoptosis Metabolism Liver X Receptor ROR FXR orally fibroblasts LXRβ foreskin T 0901317 Liver X receptor atherosclerosis LDL SKOV3 inhibit NR1H4 carcinoma CaOV3 HS-68 RAR-related orphan receptor RORγ Inhibitor T-0901317 LXRα RORα A2780 LXR ovarian N-(2,2,2-三氟乙基)-N-[4-[2,2,2-三氟-1-羟基-1-(三氟甲基)乙基]苯基]苯磺酰胺 inhibitor